Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of HIFU-AR on Blood Loss Reduction in Patients With Liver Metastases Requiring Hepatectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years at the day of consenting to the study.~* Patients with liver metastases requiring a hepatectomy for ≥ 2 segments.~* ECOG PS ≤ 1.~* Adequate bone marrow and liver function at baseline as defined below:~  * Platelet count ≥ 100 x 109/l, and hemoglobin of ≥ 9 g/dl),~ * Total bilirubin ≤ 1.5 x ULN, AST and ALT ≤ 5 x ULN.~* Recovered from prior anti-neoplasic treatment-related toxicity (grade \<2 persistent treatment-related toxicity as per CTCAE v4 are accepted).~* Willingness for follow-up visits.~* Covered by a medical insurance.~* Signed and dated informed consent document indicating that the patient has been informed of all aspects of the trial prior to enrolment.~Exclusion Criteria:~* Patients having previously undergone~  * a major hepatic surgery (i.e. more than 3 liver segments) or~ * biliary major surgery.~* Patient with cirrhosis or sinusoidal obstruction syndrome with portal hypertension.~* Pregnant women (women of childbearing potential are required to have a negative pregnancy test within 72 hours prior to inclusion). A positive urine test must be confirmed by a serum pregnancy test.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pre-coagulation by HIFU-AR (Type: EXPERIMENTAL): Pre-coagulation of the liver parenchyma with HIFU and standard liver resection
- Standard liver resection (Type: NO_INTERVENTION): Standard liver resection

Based on this trial design, predict the completion outcome and termination type (if applicable).